A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

NCT05604898 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
OTHER: Placebo
DRUG: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
OTHER: Placebo

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.